Royalty Report: Drugs, Respiratory, Disease – Collection: 282391

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Drugs
  • Respiratory
  • Disease
  • Antibody
  • Immune
  • Therapeutic
  • Drug Discovery
  • Pharmaceuticals
  • Diagnostic
  • ribonucleic acid
  • Biotechnology
  • Assay
  • Viral Infection
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282391

License Grant
Licensor grants the Licensee of the Netherlands an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensor IP, to
—  Develop, manufacture, make, have made, distribute, market, promote, sell, have sold, offer for sale, import and otherwise Commercialize Worldwide License Products in the Worldwide Territory.
—  Develop, distribute, market, promote, sell, have sold, offer for sale, import and otherwise Commercialize Limited License Products in the Limited Territory.
License Property
Licensor has developed the Limited License Products and MabIgX Platform, and includes patents.

MabIgX Technology means the Licensor technology for the identification of antibody producing B-cells,  MabIgX® Antibody Discovery Platform & Development of Rare, Potent Human mAbs.  The MabIgX technology is designed to rapidly identify rare, potent antibody-producing B-cells from patients who successfully overcame an infection, then quickly convert the discovered B-cell into a stable manufacturing substrate. This technology immortalizes and stabilizes the antibody-producing human B-cells from the patient, enabling large scale manufacturing of fully human mAbs for treatment of the masses.

AR-301, Fully Human mAb Against Staphylococcus aureus,  (or Salvecin®) is a fully human monoclonal IgG1 antibody (mAb) that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA).   AR-301 protects against alpha-toxin mediated destruction of host cells, preserving the human immune cells.

AR-105 is Broadly Active Human Monoclonal Antibody (mAb) Against Pseudomonas aeruginosa.  The Gram negative bacterium Pseudomonas aeruginosa is one of the most important public health pathogens and is associated with a number of difficult-to-treat infections such as pneumonia, bacteremia, and cystic fibrosis lung infection.  

AR-101, Fully Human mAb Against Pseudomonas aeruginosa LPS serotype O11, (or AerumabTM) is a highly specific monoclonal antibody targeted against P. aeruginosa lipopolysaccharide serotype O11. Binding of AR-101 to P. aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human phagocytes. AR-101’s mechanism of action is distinct from mechanisms of antibiotic resistance, and is effective against multidrug resistant LPS serotype O11 P. aeruginosa clinical isolates.  

AR-201, Fully Human mAb Against Respiratory Syncytial Virus, is a human IgG1 monoclonal antibody (mAb) directed against the F-protein of respiratory syncytial virus (RSV).   AR-201 was isolated from antibody-producing B-cells of an infant infected with RSV.  This mAb broadly neutralizes RSV clinical isolates, including RSV strains that are resistant to standard of care mAb Synagis®.  Licensed Product shall mean the Worldwide License Products, and the Limited License Products.

Limited License Products shall mean certain of Licensor’s products currently in development, comprising the products known as AR-301, AR-105, AR-101.

Field of Use
The field of use in each case Indication is to be a target to an infectious disease predominantly of economic impact in the Developing World.

Licensee is granted right to Licensor' clinical stage programs AR-301 (ventilator associated pneumonia), AR-105 (ventilator associated pneumonia), and AR-101 (hospital acquired pneumonia

AR-301’s mode of action is independent of the antibiotic resistance profile of S. aureus and it is active against infections caused by both MRSA and MSSA.

AR-105 (Aerucin®) is a broadly active, fully human IgG1 monoclonal antibody targeted against P. aeruginosa alginate, a widely distributed cell surface polysaccharide involved in surface adhesion, biofilm formation, and protection against the human immune system.

AR-101 is intended to be a first-line adjunctive therapy for patients with severe P. aeruginosa pneumonia being treated in intensive care units, and has orphan drug designation from the U.S. FDA and Europe’s EMA regulatory agencies.

AR-201 is engineered to have long plasma half-life sufficient to last through the duration of the RSV infection season in a single dose.

IPSCIO Record ID: 237256

License Grant
With this agreement, the English Licensor and the Licensee wish to settle legal proceedings by way of variation to the Patent License Agreement.   The original agreement is non-exclusive.
License Property
The amendment clarifies the licensed property includes, for the avoidance of doubt, Synagis.  The patent 6,632,927, is for the present invention relates to humanised antibody molecules.

Synagis is a humanized monoclonal antibody (“MAb”) approved for marketing in 1998 by the U.S. Food and Drug Administration (the “FDA”) for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (“RSV”) in pediatric patients at high risk of acquiring RSV disease (pneumonia and bronchiolitis).

Field of Use
Synagis® is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease.

IPSCIO Record ID: 239031

License Grant
The original agreement is to co-promote the Product in the Territory.  This amendment to the Agreement is to extend the special consideration for Synagis sales.
License Property
Synagis is an antibody that provides the immune system with an increased ability to prevent infection.
Field of Use
The use is for respiratory syncytial virus ('RSV'), the leading cause of lower respiratory tract infections and pneumonia in infants and children worldwide.

IPSCIO Record ID: 239029

License Grant
The RSV License Agreement amendment, between the University and Licensee, addresses the territory, Massachusetts and Maine, Net Sales, and royalties.
License Property
The property is for monoclonal antibody(ies) including, but not limited to, Synagis, which is an antibody that provides the immune system with an increased ability to prevent infection.
Field of Use
The use is for respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infections and pneumonia in infants and children worldwide.

IPSCIO Record ID: 239030

License Grant
The original agreement is to co-promote the Product in the Territory.  This amendment to the Agreement is to provide special consideration for Synagis sales.
License Property
Synagis is an antibody that provides the immune system with an increased ability to prevent infection.
Field of Use
The use is for respiratory syncytial virus ('RSV'), the leading cause of lower respiratory tract infections and pneumonia in infants and children worldwide.

IPSCIO Record ID: 118195

License Grant
The parties entered into an agreement to obtain worldwide rights to TOBI.
License Property
TOBI, is an inhaled antibiotic that was developed to treat pseudomonal lung infections. TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.  TOBI also is being used by non-CF patients with similar respiratory infections.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 263068

License Grant
Licensor granted Japanese Licensee the right to manufacture and procure such API and clinical supply, and forfeited rights to all future milestone payments related to Licensee’s development of solithromycin in Japan.  Under the terms of this Amended Agreement, Licensor is legally relieved of all obligations related to the supply of API or clinical supply to Licensee.
License Property
Solithromycin is an active pharmaceutical ingredient ('API') contained in our products and product candidates, as well as the preparation of finished products and their packaging for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues.

The Licensor is a commercial-stage pharmaceutical company focused on developing and commercializing differentiated anti-infectives for the hospital and select non-hospital, or community, settings that address the need for effective treatments for infections due to resistant gram-negative and gram-positive bacteria.  They currently market four antibiotics to treat a variety of infections caused by these resistant bacteria.

Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community acquired bacterial pneumonia (CABP) and applications for approval for both intravenous and oral capsule formulations have been accepted for review by the FDA and the EMA.  Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia.

Field of Use
Licensee owns exclusive rights to develop and commercialize solithromycin in Japan for respiratory tract infections and other indications in adults and pediatric patients.

IPSCIO Record ID: 1335

License Grant
The Licensee exclusively Licensed rights from the University, to intellectual property that relate to KB001-A.

The Licensee was granted rights to practice the invention as well as further develop antibodies to treat Pseudomonas aeruginosa (Pa) from the University.

License Property
These intellectual property rights include a method of treatment of Pa, ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa (Pa), using isolated antibodies and an antibody that specifically binds to a key target epitope, as well as diagnostic methods useful in the detection of infection by Pa.

KB001 is a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF).

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 4497

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses under Licensor's Technology to research, develop, make, have made, use, sell, offer for sale, export and import Licensor's Antibodies and Products in the Field in the Territory.
The license grants rights to all Licensor's mAbs (monoclonal antibodies) in the field of influenza discovered from their CellSpot platform.
License Property
The license provides Licensee with three fully human mAbs that bind, neutralize and protect animals from all strains of H1, H3 and B influenza, and that will also cross bind, neutralize and protect animals from all other seasonal or pandemic influenza strains that may arise (including H5N1 and H7N9).

“Antibody” means any antibody or protein comprising at least one CDR portion thereof (including multi-specific antibodies, single chain antibodies, antibody fragments, domain antibodies and conjugated antibodies) and/or similar binding protein (such as an adnectin), whether human, humanized, chimeric, murine, synthetic or from any other source.

Field of Use
“Field” means all uses for the diagnosis, treatment or prevention of influenza.

IPSCIO Record ID: 369239

License Grant
For the Grant of License, Licensor grants to the German Licensee
— an exclusive license in the Territory, with the right to grant sublicenses, under the Licensor Proprietary Information to have access to testing services performed by Licensor using the RSV Assay for the purpose of identifying Plasma donors with elevated amounts of RSV antibodies, which Plasma Licensee may use in the production of the Product and Finished Product and related purposes for sale in the Territory;
—  an exclusive license in the Territory to reference the Licensor Proprietary Information, but not obtain access to such Proprietary Information, for the purpose of seeking Regulatory Approval of the Product and Finished Product in the Territory; and,
— an exclusive license, with the right to grant sublicenses in the Territory, under the Licensor Proprietary Information to manufacture and have manufactured Product and Finished Product to be distributed in the Territory and to Commercialize the Product and Finished Product in the Territory.
License Property
Licensor is engaged in the business of developing and commercializing human plasma and plasma-derived therapeutics, including an Human Immunoglobulin with standardized elevated levels of Respiratory Syncytial Virus antibodies.

Licensor has established, qualified and validated a proprietary microneutralization assay process and procedures, through which Licensor is able to identify plasma donors with naturally occurring elevated amounts of anti-RSV antibodies, the RSV Assay.

Product means RSV, Respiratory syncytial virus, antibody enriched Human Immune Globulin bulk drug substance manufactured from human plasma containing elevated anti-RSV antibody levels that were tested using the RSV Assay.

Licensor's lead product candidate, RI-002, is a specialty plasma-derived, polyclonal, intravenous immune globulin (IGIV) derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus (CMV), measles, tetanus, etc.) as well as standardized, high levels of antibodies to respiratory syncytial virus (RSV). Licensor is pursuing an indication for the use of this specialty intravenous immune globulin (IGIV) product for treatment of patients diagnosed with PIDD.

Primary Immune Deficiency Disease (PIDD) is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly. PIDD patients are more vulnerable to infections and more likely to suffer complications from these infections.

RI-002 has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint.

Field of Use
Licensee manufactures preparations derived from human blood plasma using state-of-the-art biotechnological processes, which preparations are used as immunotherapeutic agents in the treatment of various deficiencies, diseases, infections, and other disorders.

IPSCIO Record ID: 237255

License Grant
The English Licensor grants a non-exclusive license under the Adair Patent Rights to develop, make, have made, use and sell Products in the Field and Territory.
License Property
The patents relate to Recombinant human antibodies, in the field of genetic engineering of monoclonal antibodies which are the subject of the Adair Patent Rights.

The Product shall mean antibodies or fragments thereof or any formulation containing the same of which the Licensee is the proprietor or is otherwise licensed to develop, make, have made, use or sell, and which bind to the respiratory syncitical virus (MEDI-493).

Field of Use
Field shall mean the field of human therapy and prophylaxis.

SYNAGIS is a prescription medication that is used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in children

IPSCIO Record ID: 262807

License Grant
The Company entered into an agreement with a manufacturer of the nebulizer for the use to administer Molgradex.
License Property
Molgradex (an inhalation formulation of recombinant human GM-CSF for the treatment of aPAP) for the treatment of severe pulmonary conditions.  Molgradex is administered to the lungs using the investigational eFlow® Nebulizer System.

Molgradex, is a sterile nebulizer solution in a vial containing 300 µg of molgramostim, designed to be administered once daily by inhalation via a high efficiency Investigational eFlow Nebulizer System. The PARI eFlow Nebulizer system for use with investigational drug products is a reusable electronic inhalation system that has been optimized for administration of Molgradex.

“aPAP” – autoimmune pulmonary alveolar proteinosis

“CF” –  nontuberculous mycobacterial (“NTM”) lung infection n individuals living with cystic fibrosis

AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (“MRSA”) lung infection in individuals living with CF.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 266845

License Grant
For the Exclusive License,  the Swiss Licensor grants an exclusive right and license or sublicense, as applicable, in the Territory, with the right to grant sublicenses, under the Licensor Technology and Licensor Technology Improvements to make and have made, to use and have used, to develop and have developed, to sell and have sold, to offer for sale and have offered for sale, to import and export and have imported and exported Licensed Products in the Exclusive Field in the Territory during the Term.

For the Non-Exclusive, Research License, Licensor grants a nonexclusive, research only license or sublicense, as applicable, in the Territory, with the right to grant sublicenses, under the Licensor Technology and Licensor Technology Improvements to conduct non-human studies for the development of Other Products, solely for the prevention or treatment of a Target Indication in the Target Populations.

License Property
Licensors technology is relating to the aerosolization of liquid forms of drug products and the Aerosol Devices and Disposable Dose Packs.

Licensed Product means a combination drug-device product using or otherwise practicing the Licensor Technology and delivering Pulmonary Surfactants (alone or in combination with other pharmaceutical compounds).

Drug Product means a pharmacological agent(s), including Pulmonary Surfactants, together with any excipients or inactive ingredients, formulated for use in connection with an Aerosol Device or Disposable Dose Packet.

Aerosol Device means a device to aerosolize a pharmaceutical compound for administration to humans. It is contemplated that the Aerosol Device shall consist of permanent (e.g., nondisposable) components that control power and electronics (e.g., control unit) and a physical mechanism (e.g., pump) to provide a means for dispensing the Drug Product from the container closure system.

Aerosol Technology means any technology related to the aerosolization of a liquid form of a pharmaceutical compound. Aerosol Technology does not include technology that is related to the delivery of aerosols as dry powders.

An Other Product means a combination drug-device product using or otherwise practicing the Licensor Technology and delivering pharmaceutical compounds other than Pulmonary Surfactants as an active ingredient in humans, alone or in combination with other pharmaceutical compounds, that are other than Pulmonary Surfactants.

Field of Use
Exclusive Field means the therapeutic or preventative use in humans of Aerosol Technology to deliver Pulmonary Surfactants (alone or in combination with any other pharmaceutical compound(s)) as an active ingredient for the prevention or treatment of Respiratory Indications.

Target Indications means the following Respiratory Indications Respiratory Distress Syndrome (RDS); Chronic Lung Disease (BPD); Transient Tachypnea; Hypoxemia; Pulmonary Hypertension; Pneumonia; Bronchiolitis; Diaphragmatic Hernia; Acute Lung Injury (ALI); Acute Respiratory Distress Syndrome (ARDS); Lung Transplantation; Respiratory Syncitial Virus (RSV); Cystic Fibrosis; Chronic Obstructive Pulmonary Disease (COPD); and Emphysema.

Target Populations means human patients in a Hospital Setting receiving forms of treatment for the applicable Respiratory Indication that are typically and principally provided within a Hospital Setting.

The restructure strategic alliance agreement is to unite two complementary respiratory technologies – Licensee peptide-containing synthetic surfactant technology with Licensor’ novel capillary aerosolization technology – to deliver therapeutics to the deep lung.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.